Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Idamycin PFS
(United States) [Available]Synonyms :
Class :
Antineoplastic agents: antibiotics (topoisomerase II inhibitor)
Brand Name :
Idamycin PFS
(United States) [Available]Synonyms :
Class :
Antineoplastic agents: antibiotics (topoisomerase II inhibitor)
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
Acute Lymphoblastic Leukemia(All)
12
mg/m^2
Intravenous (IV)
per day IV for 3 days in combination with cytarabine
12
mg/m^2
Intravenous (IV)
once a day
on 2, 4, 6, and 8 days in combination with tretinoin
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
Acute Lymphoblastic Leukemia(All)
5
mg/m^2
per day IV for 3 days in combination with cytarabine
5
mg/m^2
Intravenous (IV)
once a day
for 4 days in combination with cytarabine, etoposide, thioguanine, and dexamethasone
Dosage Forms & Strengths
Injectable solution
5mg/5ml
10mg/10ml
20mg/20ml
Acute Lymphoblastic Leukemia(All)
For < 60 years: 12 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age 61 to 70: 9 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age 61 to 70: 9 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
For age >70: 6 mg/m2 per day IV on days 2, 4, 6, and 8 in combination with tretinoin
may enhance the immunosuppressive effect of immunosuppressants
may diminish therapeutic effects of the vaccine
may enhance the immunosuppressive effect of immunosuppressants
may enhance the immunosuppressive effect of immunosuppressants
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
immunosuppressants such as doxorubicin may enhance the immunosuppressive effect of another drug
may increase the serum concentration and adverse effects of idarubicin by inhibiting BCRP
anthracyclines may decrease the serum concentration of digoxin
increase serum level of idarubicin by P-glycoprotein efflux transporter
increases serum level of idarubicin by P-glycoprotein efflux transporter
influenza virus vaccine trivalent
decreases therapeutic effects of influenza vaccine
increase serum level of idarubicin by P-glycoprotein efflux transporter
interaction increases toxic effects of idarubicin
interaction increases toxic effects of idarubicin
increase serum level of idarubicin by P-glycoprotein efflux transporter
increases serum level of idarubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and risk of serious infections
increase myelosuppressive effects by increasing serum concentration of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the excretion and reduce the effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance immunosuppressive effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase cardiac toxicity risk
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may diminish therapeutic effects of the vaccine
may enhance bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
enhance cardiac toxicity
may diminish the therapeutic effects of the vaccine
may enhance immunosuppressive effects of idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
decrease the metabolism of idarubicin and increase serum levels
decrease the metabolism of idarubicin and increase serum levels
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
decrease the metabolism of idarubicin and increase serum levels
decrease the metabolism of idarubicin and increase serum levels, also increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases bone marrow suppression
increases cardiac distress risk
increases immunosuppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporteridarub
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the risk of serious infections due to increased immunosuppressive effects
may enhance the adverse effects such as bone marrow suppression
increases the effects of idarubicin by inhibiting BCRP transport
eases the effects of idarubicin by inhibiting BCRP transport
immunosuppressive drugs may reduce the therapeutic effects of pidotimod
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter idaru
may enhance the adverse effects such as bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases immunosuppressive effects and increases the risk of serious infection
may diminish the therapeutic effects of sipuleucel-T
increases the effects of idarubicin by inhibiting BCRP transport
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increases the effects of idarubicin by inhibiting BCRP transport
increase bone marrow suppression
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
may increase the risk of cardiotoxicity
When idarubicin is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
Action:
Idarubicin is an anthracycline antibiotic used as a chemotherapy agent, primarily for treating certain types of leukemia. It works by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This disruption leads to DNA strand breaks and ultimately induces cancer cell death. Idarubicin also generates free radicals, contributing to its cytotoxic effects.
Spectrum:
Its spectrum of activity is mainly against hematologic malignancies, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is generally not used for solid tumors and has a narrow, disease-specific spectrum focused on leukemias.
Frequency defined:
>10%:
ECG abnormality
Ventricular premature contractions
Alopecia
Nausea
Vomiting
Weight loss
Mucositis
Anorexia
Myelosuppression
Pulmonary fibrosis
1% to 10%
Discoloration of sweat
Hyperuricemia
Diarrhea
Gastrointestinal ulcer
Discoloration of saliva
<1%
Anaphylactoid
Cardiac failure
Cardiac arrhythmia
Hepatitis
Increased serum bilirubin
Infertility
Nail banding
Idarubicin should be administered only by a healthcare professional experienced in cancer chemotherapy, particularly in the treatment of acute leukemia, and within a facility equipped to manage severe toxicities. The treatment center must be capable of addressing serious complications such as hemorrhage or life-threatening infections that may arise during therapy. The drug must be given intravenously into a well-established, freely flowing IV line; intramuscular or subcutaneous administration is strictly contraindicated due to the risk of severe local tissue injury from extravasation.
There is a significant risk of cardiac toxicity, including congestive heart failure, particularly in patients with existing heart disease or those previously treated with other anthracyclines. Myelosuppression is another major concern and can be profound at standard therapeutic doses, requiring close hematologic monitoring. Dosage adjustments are necessary for patients with renal or hepatic impairment to minimize toxicity.
Contraindication:
Hypersensitivity
Caution:
Pre-existing liver or kidney dysfunction
Cardiac risk factors
Pregnancy
Increased risk of cytotoxicity
Pregnancy: Idarubicin falls under the pregnancy category D. idarubicin can cross the placenta and can cause fetal harm.
Lactation: excretion of idarubicin in breast milk is unknown
Pregnancy category:
Idarubicin is an anthracycline antibiotic that exerts its anticancer effects primarily through DNA intercalation and topoisomerase II inhibition, disrupting DNA replication and repair, leading to cell death. It also generates free radicals, contributing to oxidative damage in cancer cells.
Pharmacokinetics:
Absorption
Peak plasma concentrations are typically reached within 1 to 5 hours after administration.
Distribution
The volume of distribution is around 64 L/kg, indicating extensive tissue penetration.
Metabolism
The drug is primarily metabolized in the liver.
Excretion and Elimination
Excretion occurs mainly through the urine, accounting for about 5% to 13% of the administered dose.
Idarubicin is administered intravenously only and must be infused into a freely flowing IV line to reduce the risk of extravasation, which can cause severe local tissue damage.
Patient information leaflet
Generic Name: idarubicin
Pronounced: eye-duh-REWB-eh-sin
Why do we use idarubicin?
Idarubicin is primarily used in the treatment of acute myeloid leukemia (AML) in adults and children, often in combination with other chemotherapeutic agents. It is also used for acute lymphoblastic leukemia (ALL), particularly in relapsed or refractory cases. Its role is mostly confined to hematologic malignancies, where it helps destroy rapidly dividing cancer cells. Idarubicin is not commonly used for solid tumors and is typically reserved for specialized leukemia treatment protocols under expert supervision.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
